- Home
- TSHA vs FDUS Comparison
TSHA vs FDUS Comparison
Compare TSHA & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- FDUS
- Stock Information
- Founded
- TSHA 2019
- FDUS 2011
- Country
- TSHA United States
- FDUS United States
- Employees
- TSHA N/A
- FDUS N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- FDUS Finance/Investors Services
- Sector
- TSHA Health Care
- FDUS Finance
- Exchange
- TSHA Nasdaq
- FDUS Nasdaq
- Market Cap
- TSHA 728.4M
- FDUS 654.0M
- IPO Year
- TSHA 2020
- FDUS 2011
- Fundamental
- Price
- TSHA $2.65
- FDUS $21.40
- Analyst Decision
- TSHA Strong Buy
- FDUS Hold
- Analyst Count
- TSHA 6
- FDUS 1
- Target Price
- TSHA $8.17
- FDUS $20.00
- AVG Volume (30 Days)
- TSHA 2.6M
- FDUS 132.6K
- Earning Date
- TSHA 08-11-2025
- FDUS 08-08-2025
- Dividend Yield
- TSHA N/A
- FDUS 10.56%
- EPS Growth
- TSHA N/A
- FDUS N/A
- EPS
- TSHA N/A
- FDUS 2.33
- Revenue
- TSHA $7,224,000.00
- FDUS $147,999,000.00
- Revenue This Year
- TSHA N/A
- FDUS $4.94
- Revenue Next Year
- TSHA N/A
- FDUS $6.51
- P/E Ratio
- TSHA N/A
- FDUS $9.19
- Revenue Growth
- TSHA N/A
- FDUS 9.06
- 52 Week Low
- TSHA $1.05
- FDUS $16.70
- 52 Week High
- TSHA $3.31
- FDUS $23.55
- Technical
- Relative Strength Index (RSI)
- TSHA 56.06
- FDUS 59.24
- Support Level
- TSHA $2.34
- FDUS $21.38
- Resistance Level
- TSHA $2.81
- FDUS $21.69
- Average True Range (ATR)
- TSHA 0.16
- FDUS 0.32
- MACD
- TSHA 0.01
- FDUS -0.01
- Stochastic Oscillator
- TSHA 67.37
- FDUS 51.06
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.